Personalizing extent of breast cancer surgery according to molecular subtypes
The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significant...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Morrow, Monica [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study - Yang, Lin ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2013 ; day:1 ; month:08 ; pages:106-109 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.breast.2013.07.020 |
|---|
| Katalog-ID: |
ELV022110593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022110593 | ||
| 003 | DE-627 | ||
| 005 | 20230625134835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2013.07.020 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013016000017.pica |
| 035 | |a (DE-627)ELV022110593 | ||
| 035 | |a (ELSEVIER)S0960-9776(13)00155-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Morrow, Monica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Personalizing extent of breast cancer surgery according to molecular subtypes |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. | ||
| 520 | |a The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. | ||
| 650 | 7 | |a Local therapy |2 Elsevier | |
| 650 | 7 | |a Local recurrence |2 Elsevier | |
| 650 | 7 | |a Molecular subtype |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Yang, Lin ELSEVIER |t The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV004843835 |
| 773 | 1 | 8 | |g volume:22 |g year:2013 |g day:1 |g month:08 |g pages:106-109 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2013.07.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.65 |j Chirurgie |q VZ |
| 951 | |a AR | ||
| 952 | |d 22 |j 2013 |b 1 |c 0801 |h 106-109 |g 4 |y 22.2013, S106-, (4 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m m mm |
|---|---|
| matchkey_str |
morrowmonica:2013----:esnlznetnobescnesreycodnt |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
44.65 |
| publishDate |
2013 |
| allfields |
10.1016/j.breast.2013.07.020 doi GBVA2013016000017.pica (DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Morrow, Monica verfasserin aut Personalizing extent of breast cancer surgery according to molecular subtypes 2013transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 https://doi.org/10.1016/j.breast.2013.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 22 2013 1 0801 106-109 4 22.2013, S106-, (4 S.) 045F 610 |
| spelling |
10.1016/j.breast.2013.07.020 doi GBVA2013016000017.pica (DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Morrow, Monica verfasserin aut Personalizing extent of breast cancer surgery according to molecular subtypes 2013transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 https://doi.org/10.1016/j.breast.2013.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 22 2013 1 0801 106-109 4 22.2013, S106-, (4 S.) 045F 610 |
| allfields_unstemmed |
10.1016/j.breast.2013.07.020 doi GBVA2013016000017.pica (DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Morrow, Monica verfasserin aut Personalizing extent of breast cancer surgery according to molecular subtypes 2013transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 https://doi.org/10.1016/j.breast.2013.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 22 2013 1 0801 106-109 4 22.2013, S106-, (4 S.) 045F 610 |
| allfieldsGer |
10.1016/j.breast.2013.07.020 doi GBVA2013016000017.pica (DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Morrow, Monica verfasserin aut Personalizing extent of breast cancer surgery according to molecular subtypes 2013transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 https://doi.org/10.1016/j.breast.2013.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 22 2013 1 0801 106-109 4 22.2013, S106-, (4 S.) 045F 610 |
| allfieldsSound |
10.1016/j.breast.2013.07.020 doi GBVA2013016000017.pica (DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.65 bkl Morrow, Monica verfasserin aut Personalizing extent of breast cancer surgery according to molecular subtypes 2013transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 https://doi.org/10.1016/j.breast.2013.07.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 22 2013 1 0801 106-109 4 22.2013, S106-, (4 S.) 045F 610 |
| language |
English |
| source |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 |
| sourceStr |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:22 year:2013 day:1 month:08 pages:106-109 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Chirurgie |
| institution |
findex.gbv.de |
| topic_facet |
Local therapy Local recurrence Molecular subtype |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| authorswithroles_txt_mv |
Morrow, Monica @@aut@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004843835 |
| dewey-sort |
3610 |
| id |
ELV022110593 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022110593</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134835.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2013.07.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013016000017.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022110593</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(13)00155-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Morrow, Monica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalizing extent of breast cancer surgery according to molecular subtypes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Local therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Local recurrence</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular subtype</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2013</subfield><subfield code="g">day:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:106-109</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2013.07.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2013</subfield><subfield code="b">1</subfield><subfield code="c">0801</subfield><subfield code="h">106-109</subfield><subfield code="g">4</subfield><subfield code="y">22.2013, S106-, (4 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Morrow, Monica |
| spellingShingle |
Morrow, Monica ddc 610 bkl 44.65 Elsevier Local therapy Elsevier Local recurrence Elsevier Molecular subtype Personalizing extent of breast cancer surgery according to molecular subtypes |
| authorStr |
Morrow, Monica |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004843835 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.65 bkl Personalizing extent of breast cancer surgery according to molecular subtypes Local therapy Elsevier Local recurrence Elsevier Molecular subtype Elsevier |
| topic |
ddc 610 bkl 44.65 Elsevier Local therapy Elsevier Local recurrence Elsevier Molecular subtype |
| topic_unstemmed |
ddc 610 bkl 44.65 Elsevier Local therapy Elsevier Local recurrence Elsevier Molecular subtype |
| topic_browse |
ddc 610 bkl 44.65 Elsevier Local therapy Elsevier Local recurrence Elsevier Molecular subtype |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| hierarchy_parent_id |
ELV004843835 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004843835 |
| title |
Personalizing extent of breast cancer surgery according to molecular subtypes |
| ctrlnum |
(DE-627)ELV022110593 (ELSEVIER)S0960-9776(13)00155-0 |
| title_full |
Personalizing extent of breast cancer surgery according to molecular subtypes |
| author_sort |
Morrow, Monica |
| journal |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| journalStr |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
106 |
| author_browse |
Morrow, Monica |
| container_volume |
22 |
| physical |
4 |
| class |
610 610 DE-600 610 VZ 44.65 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Morrow, Monica |
| doi_str_mv |
10.1016/j.breast.2013.07.020 |
| dewey-full |
610 |
| title_sort |
personalizing extent of breast cancer surgery according to molecular subtypes |
| title_auth |
Personalizing extent of breast cancer surgery according to molecular subtypes |
| abstract |
The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. |
| abstractGer |
The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. |
| abstract_unstemmed |
The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Personalizing extent of breast cancer surgery according to molecular subtypes |
| url |
https://doi.org/10.1016/j.breast.2013.07.020 |
| remote_bool |
true |
| ppnlink |
ELV004843835 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.breast.2013.07.020 |
| up_date |
2024-07-06T21:12:17.169Z |
| _version_ |
1803865646348369920 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022110593</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134835.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2013.07.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013016000017.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022110593</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(13)00155-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Morrow, Monica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalizing extent of breast cancer surgery according to molecular subtypes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Local therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Local recurrence</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular subtype</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2013</subfield><subfield code="g">day:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:106-109</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2013.07.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2013</subfield><subfield code="b">1</subfield><subfield code="c">0801</subfield><subfield code="h">106-109</subfield><subfield code="g">4</subfield><subfield code="y">22.2013, S106-, (4 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3993587 |